Racine E, Forlini C
Neuroethics Research Unit, Institut de recherches cliniques de Montréal, Department of Medicine, Université de Montréal, and Department of Neurology and Neurosurgery & Biomedical Ethics Unit, McGill University, Montréal, Canada.
J Med Ethics. 2009 Aug;35(8):469-70. doi: 10.1136/jme.2009.030460.
A recent discussion on cognitive enhancers has caused some controversy in the ethics and neuroscience fields by coming out in favour of making neuropharmaceuticals with enhancing properties available for general consumption. We highlight in this brief commentary why concerns regarding efficacy and safety, demands on resources, and public health are substantive enough to warrant serious reconsideration before pharmaceutical performance enhancement can be widely supported.
最近一场关于认知增强剂的讨论在伦理和神经科学领域引发了一些争议，该讨论支持让具有增强特性的神经药物可供大众消费。在这篇简短的评论中，我们强调为何在广泛支持药物性能增强之前，对疗效与安全性的担忧、对资源的需求以及公共卫生问题都具有足够的实质性，值得认真重新审视。
